Trials / Unknown
UnknownNCT04007484
Hemoperfusion in Acute Type A Aortic Dissection Patients Undergoing Aortic Arch Operation (HPAO)
The Effects of Hemoperfusion in Acute Type A Aortic Dissection Patients Undergoing Cardiopulmonary Bypass and Deep Hypothermic Circulatory Arrest: A Randomized, Controlled, Double-blinded Trial
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 88 (estimated)
- Sponsor
- The Second Hospital of Nanjing Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single-center, randomized, controlled, double-blind clinical trial. The main purpose of this study is to evaluate if hemoperfusion is sufficient to improve the prognosis of acute type A aortic dissection patients undergoing cardiopulmonary bypass and deep hypothermia circulatory arrest.
Conditions
- Acute Type A Aortic Dissection With Arch Involvement
- Cardiopulmonary Bypass
- Deep Hypothermic Circulatory Arrest
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Hemoperfusion | Hemoperfusion is achieved by blood filtration with a hemoperfusion device. Specifically, the hemoperfusion device composed of multiple parallel resin cartridges is connected in parallel to the oxygenator and blood reservoir and perfused at a rate of 200-250ml/min. The purpose of hemoperfusion is to decrease inflammatory mediators produced during cardiopulmonary bypass through resin cartridges adsorption, such as cytokines, free hemoglobin and other toxins. The ultimate goal of hemoperfusion is to decrease postoperative complications, improve postoperative recovery, and eventually shorten the length of hospital stay. |
Timeline
- Start date
- 2019-01-02
- Primary completion
- 2020-10-31
- Completion
- 2020-12-30
- First posted
- 2019-07-05
- Last updated
- 2020-03-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04007484. Inclusion in this directory is not an endorsement.